Quadrant wins EUA for COVID-19 saliva test

By LabPulse.com staff writers

September 24, 2020 -- Quadrant Biosciences has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Clarifi COVID-19 test kit.

Developed in partnership with State University of New York (SUNY) Upstate Medical University, the saliva swab test determines the presence or absence of SARS-CoV-2 viral RNA, according to the company. It contains a saliva collection swab and the reagents needed to perform the analysis. Clarifi is available now for clinical laboratories serving patients through physicians' offices, urgent care clinics, and hospitals, Quadrant said.

New CRISPR-based COVID-19 test shows high sensitivity
A new CRISPR-based test can produce results in 30 minutes to an hour, with similar accuracy as the standard polymerase chain reaction diagnostics now...
NIH to spend $129M to scale up COVID-19 testing
The U.S. National Institutes of Health (NIH) plans to spend about $129 million to scale up COVID-19 testing capacity and provide manufacturing support....
NIH invests almost $249M in 7 COVID-19 test technologies
The U.S. National Institutes of Health (NIH) is touting the results of its "Shark Tank" approach to spurring development in COVID-19 testing technologies,...
FDA spurs development of COVID-19 tests for use outside labs
The U.S. Food and Drug Administration (FDA) has published a template to help commercial companies develop COVID-19 molecular diagnostic and antigen tests...
A look at how COVID-19 testing varies by world region
While demand for COVID-19 testing has grown globally, the testing situation differs from region to region, writes Justin Saeks, an analyst with market...

Copyright © 2020 LabPulse.com

Last Updated np 9/29/2020 4:50:55 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email